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Robert Tran, M.D., Jang-Hyeon Cho, Ph.D., Ming-Jer Tsai, Ph.D.,
Travis J. Bailey, Ph.D., Milan Jamrich, Ph.D., Marvin E. Ament, M.D.,
William R. Treem, M.D., Ivor D. Hill, M.D., Jorge H. Vargas, M.D.,
George Gershman, M.D., Douglas G. Farmer, M.D.,
Laurie Reyen, M.N., and Martín G. Martín, M.D.
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Background
From the Department of Pediatrics, Division of Gastroenterology and Nutrition, Mattel Children’s Hospital (J.W., R.T.,
M.E.A., J.H.V., M.G.M.); the Department
of Pathology and Laboratory Medicine
(G.C.), Center for Ulcer Research and Education, Division of Digestive Diseases,
the Department of Medicine (S.V.W.), and
the Departments of Surgery (D.G.F.) and
Nursing (L.R.), David Geffen School of
Medicine, UCLA — all in Los Angeles; the
Department of Molecular and Cellular Biology ( J.-H.C., M.-J.T., M.J.) and Program
in Developmental Biology (M.-J.T., T.J.B.,
M.J.), Baylor College of Medicine, Houston;
the Department of Pediatrics, Division of
Gastroenterology, Hepatology, and Nutrition, State University of New York Downstate College of Medicine, Brooklyn (W.R.T.);
the Department of Pediatrics, Division of
Gastroenterology, Wake Forest University School of Medicine, Winston-Salem, N.C.
(I.D.H.); and the Department of Pediatrics,
Division of Gastroenterology at Harbor–
UCLA Medical Center, David Geffen School
of Medicine, UCLA, Torrance, Calif. (G.G.).
Address reprint requests to Dr. Martín at
the David Geffen School of Medicine,
UCLA, Department of Pediatrics, Gastroenterology, and Nutrition, 10833 Le Conte
Ave., 12-383 MDCC, Los Angeles, CA 90095,
or at mmartin@mednet.ucla.edu.

Neurogenin-3 (NEUROG3) is expressed in endocrine progenitor cells and is required
for endocrine-cell development in the pancreas and intestine. The NEUROG3 gene
(NEUROG3) is therefore a candidate for the cause of a newly discovered autosomal
recessive disorder characterized by generalized malabsorption and a paucity of enteroendocrine cells.
Methods

We screened genomic DNA from three unrelated patients with sparse enteroendocrine cells for mutations of NEUROG3. We then tested the ability of the observed
mutations to alter NEUROG3 function, using in vitro and in vivo assays.
Results

The patients had few intestinal enteroendocrine cells positive for chromogranin A,
but they had normal numbers of Paneth’s, goblet, and absorptive cells. We identified
two homozygous mutations in NEUROG3, both of which rendered the NEUROG3 protein unable to activate NEUROD1, a downstream target of NEUROG3, and compromised
the ability of NEUROG3 to bind to an E-box element in the NEUROD1 promoter. The
injection of wild-type but not mutant NEUROG3 messenger RNA into xenopus embryos induced NEUROD1 expression.
Conclusions

A newly discovered disorder characterized by malabsorptive diarrhea and a lack of
intestinal enteroendocrine cells is caused by loss-of-function mutations in NEUROG3.

N Engl J Med 2006;355:270-80.
Copyright © 2006 Massachusetts Medical Society.
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P

atients with congenital diarrhea
generally present within the first weeks
after birth with severe, life-threatening watery diarrhea that can be classified as either secretory or malabsorptive in nature.1 Routine clinical
evaluation, including intestinal biopsy, may be
used to further categorize the diarrhea according
to the severity of the inflammation and to assess the integrity of the crypt–villus axis and the
architecture of the epithelial layer. On the basis
of both clinical and pathological characteristics, various specialized formulas may be used
to minimize the diarrheal symptoms, although
some children require extended periods of intravenous nutrition to sustain normal growth and
development.
Many patients with congenital diarrhea in
early infancy have a selective defect in one of a
variety of transporters and enzymes that have
nonredundant roles in the processes of nutrient
assimilation and ion absorption.2 In contrast,
generalized malabsorptive disorders involving
simple nutrients (such as monosaccharides and
amino acids) result from a nonselective decline
in the capacity to absorb nutrients, which is due
to either a decrease in the small-bowel surface
area or mucosal inflammation.1 Thus far, defects
in the structure and function of absorptive and
inflammatory cells of the gut have been associated with diarrhea and the alteration of ion and
nutrient absorption and secretion.
Studies involving mice have shown that two
basic helix–loop–helix transcription factors —
mouse atonal homologue 1 (encoded by Math1)
and Neurogenin-3 (Neurog3, encoded by Neurog3)
— influence the fates of enteroendocrine, Paneth’s, goblet, and enterocyte cells.3-6 Neurog3−/−
mice lack endocrine cells in the pancreas and intestine, which is presumably why they die of diabetes during the first several days of life.3 These
and other findings suggest that Neurog3 is a key
transcription factor that controls the fate of endocrine cells in both the pancreas and intestine.3-6 Despite its clear role in the development
of endocrine cells, no disease-causing mutation
of NEUROG3 (or of the genes encoding the closely
related NEUROG1 and NEUROG2) has to our
knowledge been described in humans.7 We studied three boys with severe generalized congenital
malabsorptive diarrhea to determine the clinical
characteristics and molecular basis of this disorder in humans.

n engl j med 355;3

Me thods
Patients

We identified three boys with similar clinical characteristics and obtained informed, written consent
from the legal guardians of each patient. The study
protocol was approved by the institutional review
board of the University of California at Los Angeles. Pertinent medical and pathology records were
obtained and summarized for each patient.
Pathological Analysis of the Intestine

We analyzed formalin-fixed, paraffin-embedded
biopsy samples of intestinal tissue using immunohistochemical techniques and stained them
with hematoxylin and eosin and periodic acid–
Schiff. We carried out immunohistochemical assays for chromogranin A (Dako), synaptophysin
(Dako), lysozyme (Dako), serotonin (Zymed), gastrin (Dako), somatostatin (Dako), and vasoactive
intestinal polypeptide (Biogenics) with standard
techniques and using commercially available antibodies, according to the manufacturers’ instructions. Archival samples of small bowel were used
as control samples. Electron microscopy was used
to examine biopsy samples of the small-intestinal
mucosa from each patient. Information on DNA
sequencing, cloning, site-directed mutagenesis,
messenger RNA (mRNA) and protein synthesis,
and analysis in xenopus embryos can be found in
the Supplementary Appendix, available with the
full text of this article at www.nejm.org.

R e sult s
Overview of Clinical Histories

The patients presented during the first several
weeks of life with vomiting, diarrhea, dehydration,
and a severe hyperchloremic metabolic acidosis
after the ingestion of standard cow’s-milk–based
formula (Table 1 and the Supplementary Appendix). They were readmitted on several occasions
during the first month of life when it became
clear that they all had chronic unremitting diarrhea that was malabsorptive in nature. Comprehensive evaluations for allergic, immunologic, infectious, and metabolic causes of diarrhea were
all negative. The pancreatic exocrine function was
normal in all three patients. The radiographic evaluation of Patients 1 and 2 showed that the length
and orientation of the small bowel were normal.
Biopsy of the stomach and esophagus revealed
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Table 1. Baseline Characteristics of the Patients.*
Characteristic

Patient 1

Patient 2

Patient 3

Age

35 mo

8 yr

9 yr

Sex

M

M

M

Birth weight — g

2530

2720

2334

Hyperchloremic metabolic acidosis

Yes

Yes

Yes

Cessation of diarrhea while receiving nothing by mouth

Yes

Yes

Yes

Viral, parasitic, and bacterial pathogens

None

None

None

Sweat chloride test and test for CF DNA

Normal

Normal

Normal (CF DNA ND)

Mitochondrial DNA

Normal

Normal

ND

Lactate and pyruvate

Normal

Normal

ND

Serum amino acids

Normal

Normal

Normal

Urine organic acids

Normal

Normal

Normal

Cholesterol and triglyceride panel

Normal

Normal

Normal

Apolipoprotein profile

Normal

Normal

ND

Zinc, ammonia, and creatine kinase

Normal

Normal

ND

HIV-1 or HIV-2 antibody

Negative

Negative

Negative

T-cell and B-cell subgroups

Normal

Normal

Normal

Stool
Trypsin activity

Maximum (+4)

ND

ND

Reducing substances

Maximum (+2)

Maximum (+2)

Maximum (+2)

Normal

Mild elevation

ND

Mucosal lactase, sucrase, and maltase
activity

Alpha-1-antitrypsin activity

Normal

Normal

Normal

Upper gastrointestinal and small-bowel
follow-through

Normal

Normal

ND

ND

Normal

Normal

Secretin stimulation test (pancreatic
enzymes)

normal histologic features and biopsy of the duodenum and sigmoid colon revealed histologic features initially interpreted as normal. The activity
of various mucosal disaccharidases was within
the normal range.
The volume of diarrhea in all three patients
was in the range of 60 to 120 ml per kilogram of
body weight per day (normal stool volume, less
than 20). The diarrhea ceased during periods of
fasting. Water was well tolerated, but the administration of a glucose-based oral rehydration solution led to diarrhea. Two patients continued to
have diarrhea while being fed a carbohydrate-free
cow’s-milk–based formula, and the addition of
either fructose or glucose exacerbated the severity of the diarrhea. Several amino acid–based formulas, including one without carbohydrates, were
administered but did not lead to resolution of
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the diarrheal symptoms in two patients. Patient 1
even had diarrhea when long- or medium-chain
triglycerides or amino acids (typically used for
parenteral nutrition) were added to the drinking
water.
All three children were eventually discharged
home with the means of delivering and receiving
parenteral nutrition and limited enteral feeding
and were readmitted on several occasions because
of sepsis related to an infection from the central
venous catheter. Parenteral nutrition was discontinued in the third patient because of the severity
and frequency of such sepsis. Severe cholestatic
liver disease and portal hypertension developed
in the index patient (Patient 1), and by two years
of age the patient underwent a native subtotal enterectomy and total hepatectomy and received an
orthotopic en bloc liver–intestine transplant. He
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Table 1. (Continued.)
Characteristic

Patient 1

Patient 2

Patient 3

Normal

Normal

Normal

Response to various nutrients†
Water
Water + MCT

Diarrhea

ND

ND

Water + LCT

Diarrhea

ND

ND

Water + amino acids

Diarrhea

ND

ND

Glucose-based oral rehydration solution

Diarrhea

Diarrhea

Diarrhea

Carbohydrate-free formula

Diarrhea

Diarrhea

? Decreased

Carbohydrate-free formula + fructose

Diarrhea

Diarrhea

? Decreased

Carbohydrate-free formula + glucose

Diarrhea

Diarrhea

Diarrhea

Amino acid–based formulas

Diarrhea

Diarrhea

Diarrhea

Carbohydrate-free, amino acid–based
formula

Diarrhea

ND

ND

Cow’s-milk–based formula

Diarrhea

Diarrhea

Diarrhea

Soy-protein–based formula

Diarrhea

Diarrhea

Diarrhea

Pancreatic enzymes

Diarrhea

Diarrhea

Diarrhea

Loperamide

Diarrhea

Diarrhea

ND

Cholestyramine

Diarrhea

Diarrhea

Diarrhea
Yes (2 mo)

Response to drug management (during receipt of cow’s-milk–based formula)

Clinical course
Received home PN (duration)

Yes (24 mo)

Yes (23 mo)

Currently receiving PN

No‡

No

No

Current diarrhea

No‡

Yes

Yes

Small-bowel transplantation

Yes

No

No

* CF denotes cystic fibrosis, ND not done, HIV human immunodeficiency virus, MCT medium-chain triglycerides,
LCT long-chain triglycerides, and PN parenteral nutrition.
† Diarrhea is defined as diarrhea with a volume of more than 20 ml per kilogram of body weight per day.
‡ Patient died of sepsis when manuscript was under review.

did well, without diarrhea and while being fed
enterally, for nearly a year but then died unexpectedly of sepsis. The second patient continued to
receive parenteral nutrition at home until the age
of two years, and since then, he has been receiving supplemental oral vitamins and electrolytes.
Patients 2 and 3 continue to have large-volume
loose stools daily, and their weights are either at
or below the 5th percentile for age. Type 1 diabetes developed in both patients when they were
8 years old.
Histopathological Analysis of the Intestine

We obtained small-bowel–biopsy samples from
the index patient at various ages; these samples
consistently revealed a normal villus structure and
no pathologic infiltration of inflammatory cells

n engl j med 355;3

(Fig. 1). Extensive evaluation of the small- and
large-bowel mucosa after enterectomy showed
profound dysgenesis of the enteroendocrine cells
(compare Fig. 1D with Fig. 1E). The appearance
of the remaining mucosa, including the Paneth’s
and goblet cells, was normal (Fig. 1A, 1B, and 1C).
Staining for chromogranin A revealed only one
enteroendocrine cell (which was aberrant in shape)
in the more than 350 small-bowel crypts examined
(Fig. 1D) and none in the colon. In contrast, five
or six enteroendocrine cells were present per crypt
in normal mucosa (Fig. 1E). The lack of cells was
also observed in biopsy specimens obtained from
the index patient 18 months before enterectomy.
Staining of small-bowel–biopsy samples for chromogranin A also revealed a dramatic depletion
of enteroendocrine cells in Patients 2 and 3. Only
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D
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Figure 1. Sample of Small Bowel with Sparse Enteroendocrine Cells from Patient 1.
The crypt and villus architecture was normal (hematoxylin and eosin, Panel A), as were goblet cells (periodic acid–
Schiff, Panel B) and Paneth’s cells (antilysozyme, Panel C), but there was a deficiency of enteroendocrine cells (antichromogranin, Panel D), as compared with the number in a control sample (antichromogranin, Panel E).

1 cell was identified in 100 crypts in the duodenum, and 8 were identified in 100 crypts in the
jejunum.
The lack of the general endocrine marker synaptophysin also indicated an extreme deficiency
of endocrine cells in the three patients. Only 1 cell
in 350 crypts was positive for serotonin. No cells
containing gastrin or somatostatin were identified
in more than 300 crypts, and as expected, vasoactive intestinal polypeptide stained only nerves
(data not shown). The results of electron microscopy indicated that the patients had normal brush
borders, microvilli, intracellular mitochondria, and
tight junctions. We observed an occasional lipidladen enterocyte in the upper third of the villus,
an abnormal finding previously described in patients with abetalipoproteinemia and hypoproteinemia.1

blood samples from the index patient and observed
a homozygous missense change predicted to result in the substitution of a serine residue for an
arginine residue at position 107 (R107S) (Fig. 2).
The other two patients had a homozygous missense change predicted to result in the substitution of a leucine residue for an arginine residue at
position 93 (R93L) (Fig. 2). Position 107 is in the
first helix of the protein, which is critical to the
activation of downstream genes. Position 93 is in
the DNA-binding or basic domain (i.e., the region
that binds the promoters of genes regulated by
NEUROG3), just upstream of the first helix (Fig.
2B). We did not observe these mutations in specimens from 100 ethnically matched control persons (data not shown). The arginine residues at
positions 93 and 107 are conserved in all known
neurogenin proteins across a wide range of species, including Caenorhabditis elegans (Fig. 2B). We
Sequencing of NEUROG3
hypothesize that the missense mutations result in
We hypothesized that the enteroendocrine-cell dys- loss of function of the protein because of their
genesis was caused by a null mutation of NEUROG3. critical location and the extent to which the afWe therefore sequenced NEUROG3 in DNA from fected residues are conserved across species.
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A

Ser
93
Arg

Asn

95
Arg

Met

His

Asn

Leu

100
Asn

Ser

Ala

Leu

Asp

105
Ala

Leu

Arg

108
Gly

Patient 1

Patients
2 and 3

Leu

B
Basic

Helix I

Loop

Helix II

bHLH domain
82

95

138

190 214
Neurogenin-3

Species
Homo sapiens
H. sapiens
H. sapiens
Mus musculus
M. musculus
M. musculus
Rattus norvegicus
R. norvegicus
Canis familiaris
Gallus gallus
G. gallus
Danio rerio
D. rerio
D. rerio
Cynops pyrrhogaster
Xenopus laevis
X. laevis
Caenorhabolitis elegans

Neurogenin
3
2
1
3
2
1
3
1
3
2
1
3
2
Unknown
Unknown
1a
1b
1

Basic
domain

bHLH
domain

Activation
domain

R P K S E L A L SKQRRSRRKKANDRERNRMHNLNSALDALRGVLPTFPDDAKL
G A K T A E T V QRIKKTRRLKANNRERNRMHNLNAALDALREVLPTFPEDAKL
R V R S E A L L HSLRRSRRVKANDRERNRMHNLNAALDALRSVLPSFPDDTKL
R P K S E L A L SKQRRSRRKKANDRERNRMHNLNSALDALRGVLPTFPDDAKL
G A K T A E T V QRIKKTRRLKANNRERNRMHNLNAALDALREVLPTFPEDAKL
R V R S E A L L HSLRRSRRVKANDRERNRMHNLNAALDALRSVLPSFPDDTKL
R V R S E A L L HSLRRSRRVKANDRERNRMHNLNAALDALRSVLPSFPDDTKL
R V R S E A L L HSLRRSRRVKANDRERNRMHNLNAALDALRSVLPSFPDDTKL
R P K S E L A L SKQRRSRRKKANDRERNRMHNLNSALDALRGVLPTFPDDAKL
A A R T A E T A QRIKRSRRLKANNRERNRMHNLNAALDALRDVLPTFPEDAKL
R A R T E A L L HTLKRSRRVKANDRERNRMHHLNAALDELRSVLPTFPDDTKL
K L K K L M S T SRQRGNRRVKANDRGRHRMHNLNSALDNLRSVLPTFPDDAKL
R A R N E T T V HVVKKNRRLKANDRERNRMHNLNDALDALRSVLPAFPDDTKL
R A R N E T T V HVVKKNRRLKANDRERNRMHNLNDALDALRSVLPAFPDDTKL
R V K S E A I Q HSIKKNRRVKANDRERNRMHSLNYALDKLRCILPSFPDDTKL
- G K S G E- T V LKIKKTRRVKANNRERNRMHNLNSALDSLREVLPSLPEDAKL
- - - - G D T V LKIKKTRRVKANNRERNRMHHLNYALDSLREVLPSLPEDAKL
R K R S P A T I ERAKTVRRDKANARERRRMNSLNDALEHLRGILPALPDEPKM

R93L

R107S

Patients 2 and 3

Patient 1

119
148
128
119
148
129
129
129
119
114
78
114
106
106
114
117
121
98

Figure 2. Sequence of NEUROG3 (Panel A) and Structure of the Protein (Panel B).
Panel A shows the NEUROG3 sequence in Patient 1 (top) and in Patients 2 and 3 (bottom). The human NEUROG3
gene (region encoding amino acids 93 to 108) is shown, and the specific mutations are indicated by the arrows. Patient 1
had a homozygous mutation resulting in the substitution of serine for arginine in residue 107 (R107S), whereas Patients 2 and 3 had a homozygous mutation resulting in the substitution of leucine for arginine in residue 93 (R93L).
Panel B shows the structure of NEUROG3, including the basic helix–loop–helix (bHLH) domain. The conservation
of various residues within this domain is shown for all members of the neurogenin family in a wide variety of species. Unknown means that the specific type of neurogenin is unknown. Dashes represent amino acids unrelated to
the neurogenin family. The numbers to the right of the sequences are the residue numbers for the last amino acid
listed for each species.
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Transactivation of the NEUROD1 Promoter

When bound to another transcription factor,
E47, NEUROG3 activates the transcription of the
NEUROD1 gene.8 More specifically, the NEUROG3–
E47 heterodimer binds two well-characterized
E-box DNA elements (called E-box 1 and E-box 3)
that lie in the promoter region of NEUROD1; such
binding is critical to the activation of NEUROD1
by the heterodimer.8 A reporter vector composed
of the three E-boxes in the promoter region of
NEUROD1 followed by the luciferase gene was cotransfected, together with a wild-type NEUROG3
expression vector, into HeLa cells. The resulting
promoter activity was five times that of the negative control (Fig. 3A). We observed insignificant
promoter activity, however, when we replaced the
wild-type NEUROG3 expression vector with a vector encoding either the R93L or R107S NEUROG3
mutant. A Western blot of transfected, flag-tagged
NEUROG3 revealed approximately equal amounts
of the wild-type and mutant forms (Fig. 3B). We
therefore concluded that the mutations render
NEUROG3 incapable of inducing NEUROD1 gene
expression in this transient-transfection assay.
Interaction between NEUROG3
and the NEUROD1 Promoter

To clarify the mechanism by which the mutations of NEUROG3 prevented the activation of the
NEUROD1 promoter, we assessed the ability of each
mutant protein to interact in vitro with an E-box
in the NEUROD1 promoter. The E47 homodimer
bound to the E-box 1 DNA element in a specific
manner (lane 2 in Fig. 3C). Wild-type NEUROG3,
on the other hand, failed to bind DNA in the absence of E47 (data not shown), but the NEUROG3–
E47 heterodimer formed an abundant and specific complex, indicating robust binding between
the heterodimer and the DNA element (lanes 3, 4,
and 5 in Fig. 3C). In contrast, mutant NEUROG3
(encoded by constructs containing the R93L or
R107S mutation) generated less signal than the
wild-type NEUROG3, indicating weaker binding
(lanes 6 through 11 in Fig. 3C). Approximately
equal amounts of E47 and NEUROG3 (both wildtype and mutant forms) were used in this analysis (Fig. 3D). These data suggest that the failure
of mutant NEUROG3 to augment the NEUROD1
promoter activity is due, at least in part, to its compromised ability to bind the NEUROD1 promoter.
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Figure 3 (facing page). In Vitro Effects of NEUROG3
on the NeuroD1 Promoter.
The clone containing the NeuroD1 promoter (NeuroD1-3E)
was cotransfected into HeLa cells with either wild-type
or mutant (R107S or R93L) NEUROG3 expression vectors. Panel A shows the resulting activity of firefly luciferase per unit of renilla luciferase, relative to that of the
negative control: NeuroD1-3E cotransfected with the
expression vector containing the mutant NEUROG3
(R93L) cloned in the antisense orientation. The TATA
vector is the proximal promoter region of NeuroD1 that
lacks the E-boxes. Values are means ±SE of six replicates
from three different experiments. Panel B shows the results of Western blotting, with anti-flag M2 and anti–
β-actin antibodies, of the whole-cell lysate from HeLa
cells into which flag-tagged wild-type and mutant
NEUROG3 vectors had been transiently transfected
24 hours earlier. “None” represents cells into which
NEUROG3 was not introduced. β-Actin served as an
internal control for the equal loading of protein. Panel
C shows the binding of a NeuroD1 promoter element
to NEUROG3–E47. An electrophoretic mobility shift
assay was performed with the use of a recombinant
protein (E47 or NEUROG3–E47) and a labeled duplex
oligonucleotide (NeuroD1 E-box 1). Recombinant E47
alone (lane 2), with wild-type NEUROG3 (lanes 3, 4,
and 5), or with mutant NEUROG3 — R107S (lanes 6,
7, and 8) or R93L (lanes 9, 10, and 11) — bound to the
oligonucleotide duplexes. The formation of complexes
with the labeled oligonucleotide duplexes lessened
proportionally in the presence of 10 and 100 times the
baseline amount of unlabeled oligonucleotide duplexes
(increasing levels indicated by the increasing slope of
the black triangles). Panel D shows the results of the in
vitro translation of E47 and NEUROG3 (wild-type and
mutant forms) labeled with [35S]methionine and visualized on a 12 percent acrylamide gel to confirm their
relative sizes and abundances.

In Vivo Activation of NEUROD1

The ectopic injection of NEUROG3 RNA into xenopus embryos induces the expression of NeuroD1
in neurons.8 We therefore tested the ability of mutant NEUROG3 to transactivate NeuroD1 production in vivo by injecting mouse Neurog3 mRNA
(wild-type or mutant) into xenopus embryos and
then evaluating NeuroD1 levels (Fig. 4). The human
and mouse orthologues of the protein showed
a high degree of similarity (72 percent overall
and 98 percent in the critical helix–loop–helix
DNA-binding domain), and we were unable to
detect significant differences in the extent to which
they activated NEUROD1. Wild-type Neurog3 mRNA
induced ectopic NeuroD1-positive neurons in the
injection side of the embryo (Fig. 4B). We observed
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no such neurons in the sham-injected control or
in the side that was not injected (Fig. 4A) and very
few, if any, in the embryos injected with either of
the two mutant forms of mRNA (Fig. 4D and 4F).
These results suggest that the mutations attenuate NEUROG3 function in vivo.

tinal absorptive cells (enterocytes) and secretory
cells (enteroendocrine, Paneth’s and goblet cells)
has profound effects on the capacity of the small
intestine to absorb nutrients. Specifically, the clinical findings highlight a critical role of enteroendocrine cells in augmenting nutrient absorption.
We have named the disorder exemplified by these
cases “enteric anendocrinosis.”
Dis cus sion
The fate of the embryonic or adult stem cell
Our findings indicate that disruption of the path- is determined by a series of molecular switches.
way that determines the differentiation of intes- The first switch is the lateral inhibition by a ligand
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B Injected, Wild-type Neurog3

A Not Injected
DRG

TG
Eye

500 μm

C Not Injected

D Injected, Mutant Neurog3 (R107S)

E Not Injected

F Injected, Mutant Neurog3 (R93L)

Figure 4. In Vivo Activation of NeuroD1 by NEUROG3.
Panel A shows the normal expression of NeuroD1 in the eye, trigeminal
ganglia (TG), and dorsal-root ganglia (DRG) of a Xenopus laevis embryo.
Shown are the side of each embryo that was injected (Panels B, D, and F)
and not injected (Panels A, C, and E) with wild-type mouse Neurog3 (Panels A and B) or mutant mouse Neurog3 — R107S (Panels C and D) or R93L
(Panels E and F). Some areas are magnified (insets), and some ectopic
NeuroD1-positive neurons are marked by arrow (Panel B).

of the Notch receptor.9,10 In the cells that express
it, the ligand triggers a signaling cascade dominated by the sequential expression of numerous
basic helix–loop–helix transcription factors, such
as MATH1.5,11,12 Cells expressing the Notch receptor, on the other hand, are induced (through the
binding of the Notch receptor by one of its ligands)
to inhibit this cascade of basic helix–loop–helix
transcription factors — resulting in the exclusive
development of absorptive cells.9,11-13 This inhibition is mediated by a molecule called Hairy and
Enhancer of Split (HES1): its expression is induced through the activation of the Notch receptor, and it inhibits the cascade of basic helix–
loop–helix transcription factors by preventing the
expression of MATH1.
The intestines of Math1−/− mice lack secretory
cells, and the mice inexplicably die soon after
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birth. Neurog3 expression is abrogated in Math1null mice, suggesting that Neurog3 is a downstream
target of Math1. Unlike their Math1-null counterparts, Neurog3-null mice have normal goblet and
Paneth’s cells and no islet cells in the pancreas,
and like Math1−/− mice, they lack enteroendocrine
cells.3-6 Diarrhea has not been described in either
strain of mouse. Although diabetes has been suggested as the cause of death of Neurog3-null mice,
Math1-null mice presumably have normal pancreatic function, because Math1 is not expressed in
the pancreas.5 Combining the data from mouse
knockout studies and our findings, it appears that
loss-of-function mutations of NEUROG3 contribute
to early death by causing a severe malabsorptive
diarrhea.
The particular hormone factors and paracrine
factors downstream of NEUROG3 that affect nutrient absorption have yet to be identified.14 They
may lie downstream of transcription factors activated by Neurog3: NeuroD1, Pdx1, or both.15,16
Mice deficient in either NeuroD1 or Pdx1 lack a
subgroup of enteroendocrine cells, but because
they die shortly before or after birth, the relevance
of a deficiency of a portion of enteroendocrine
cells to early death is uncertain, and diarrhea has
not been described in these mice. An assortment
of null mice, with selective deficiencies of specific
hormones secreted by the enteroendocrine cells,
have been created.14-18 Many of these mice have
specific physiological phenotypes, but none have
been described as having the malabsorption, malnutrition, or perinatal death that would mimic the
clinical findings in our patients.
Two other findings, together with our results,
indicate that enteroendocrine cells and their products have a profound role in the capacity of the
small intestine to absorb simple nutrients. First,
the transient depletion of enteroendocrine cells
was reported in a patient with temporary malabsorption and the autoimmune polyglandular syndrome type I; the symptoms resolved after the
spontaneous recovery of enteroendocrine cells.19
Second, a mutation of the gene encoding the enzyme prohormone convertase 1 has been reported
to result in malabsorption, obesity, hypoadrenalism, and elevated levels of prohormones with a
proportionate depletion of mature hormones.20
This family of enzymes is located in enteroendocrine and other endocrine cells and converts inactive peptide hormone precursors into their mature
functional forms.20,21
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How does an absence of enteroendocrine cells
lead to malabsorptive diarrhea? Sensors that prime
the intestine for the absorption of luminal nutrients have long been suggested to play a critical
role in intestinal adaptation.22 However, their precise identity, location, and function have remained
elusive. Various nutrient, pH, and osmotic sensors
are present in enteroendocrine cells and submucosal cholinergic neurons, but the intracellular
signals of these sensors and their subsequent effector products are not well understood.23-25
A paucity of enteroendocrine cells might lead
to generalized malabsorption if it decreased intestinal transit time.1 Although we did not carry
out gastric-emptying studies in our patients, the
results of barium imaging of two of the cases suggested normal luminal transit. Cholinergic neurons clearly influence intestinal motility and can
be influenced by effector products secreted by
adjacent enteroendocrine cells.26,27 However, the
index patient was intolerant to simple amino acid
solutions, suggesting that rapid transit by itself
would not be likely to lead to such profound malabsorption.
Our patients and Neurog3−/− mice were found
to have normal disaccharidase activities; the mice
have normal targeting of lactase to the brush-border membrane, suggesting that the apical targeting of these enzymes is not defective.6 Although
NEUROG3 is not abundantly expressed in enterocytes, most genes that express proteins with important roles in nutrient assimilation are augmented by a hepatocyte nuclear factor (HNF1).28
Since HNF1 is known to form a heterodimer with
NEUROG3, the absorptive capacity of the enterocyte may be deleteriously affected in the absence
of the NEUROG3–HNF1 complex.29 The localization and abundance of brush-border enzymes and
transporters in humans with a deficiency of
NEUROG3 have yet to be analyzed. Alternatively,
the presence of progenitor or mature enteroendoReferences
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